Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592319 · ClinicalTrials.gov registry record · Phase 2
Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
A Phase 2 study, sponsored by Boston University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00592319 is a Phase 2 study that was terminated before completion, run by Boston University. The registered enrollment target is 10 participants.
The verdict
NCT00592319, a Phase 2 study, was terminated before completion, sponsored by Boston University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Respiratory recurrent papilloma (RRP) is one of the most common benign tumors. Surgical removal is the current management for RRP, but it is a very traumatic procedure, and often leads to permanent voice dysfunction. In this study, we will develop a new, combined RRP treatment with a pulsed dye laser (PDL) and Celebrex. We will determine if Celebrex, a newly developed inhibitor of cyclooxygenase (COX)-2, can provide a long-term inhibitory effect on RRP, therefore preventing RRP from recurring. This combined strategy, if successful in this proposed study, will provide a new and ideal "voice-preserving" therapy for RRP that will deliver long-term efficacy in managing RRP.
Interventions
- DRUG Celebrex
- DEVICE PDL
- PROCEDURE CO2 laser or microsurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592319
The ClinicalTrials.gov registry entry for NCT00592319 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Celebrex is the first listed.
NCT00592319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592319 about?
NCT00592319 is a clinical study titled "Celebrex (Celecoxib) Treatment of Laryngeal Papilloma". Respiratory recurrent papilloma (RRP) is one of the most common benign tumors. Surgical removal is the current management for RRP, but it is a very traumatic procedure, and often leads to permanent voice dysfunction. In this study, we will develop a new, combined RRP treatment with a pulsed dye lase...
What is the current status of trial NCT00592319?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2005-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00592319?
The interventions under investigation include: Celebrex (DRUG), PDL (DEVICE), CO2 laser or microsurgery (PROCEDURE).
Who is sponsoring clinical trial NCT00592319?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.